Full Text View
Tabular View
No Study Results Posted
Related Studies
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
This study is currently recruiting participants.
Study NCT00524797   Information provided by Ziv Hospital
First Received: September 2, 2007   No Changes Posted

September 2, 2007
September 2, 2007
September 2007
 
 
 
No Changes Posted
 
 
 
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy

Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. Death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs) are widely used in the treatment of chemotherapy induced neutropenia. The same Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments are expensive and have several side effects.

In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life.

The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia.

This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.

 
 
Interventional
Prevention, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Myelosuppression
Dietary Supplement: Profonycia
Active Comparator: 50 patients will receive Profonycia 5 gr/day PO for 7 days
Zidan J, Shetver L, Gershuny A, Abzah A, Tamam S, Stein M, Friedman E. Prevention of chemotherapy-induced neutropenia by special honey intake. Med Oncol. 2006;23(4):549-52.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
50
 
 

Inclusion Criteria:

Patients 18 years old or elder receiving chemotherapy 1/2-3 weeks

Exclusion Criteria:

Patients below 18 years old

Both
18 Years to 80 Years
No
Contact: Zidan Jamal, Prof +972 4 6828951
Israel
 
NCT00524797
 
HP 7-260 S
Ziv Hospital
 
Principal Investigator: Zidan Jamal, Prof Ziv MC
Ziv Hospital
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP